Swedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease conference in Boston.
Link as first comment.
@longevitytech.bsky.social
@longevitytech.bsky.social
@longevitytech.bsky.socialSwedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease conference in Boston.
Link as first comment.